DotBio, a biotech firm focused on developing novel immuno-oncology drugs, has closed its Series A funding round, securing $5.6M. The company leverages its proprietary DotBody technology to create multi-specific, humanized, and highly-stable domain therapeutic antibodies.
This innovative approach was conceptualized by founders Professor P盲r Nordlund and Dr. Ignacio Asial. Their expertise in protein and antibody engineering, developed at Singapore鈥檚 Nanyang Technological University, underpins the DotBody technology.
